79:
As of March 2014, Ambit sought to develop new therapeutics through internal, proprietary research, which is evidenced by their pipeline of three products consisting entirely of internally developed therapeutics. Further, Ambit aimed to be a full
67:
In June 2010, Ambit completed a Series D-2 round of equity financing, raising $ 30 million in new capital. The investor syndicate was led by
Apposite Capital LLP and included existing investors such as Perseus-Soros Biopharmaceutical Fund,
380:
385:
370:
223:
199:
350:
The SEC 10K submission for 2013 indicates that the company is a "biopharmaceutical" company, which implies that they are primarily developing
375:
265:
316:
291:
354:; however, their lead product is a small molecule therapeutic, calling into question the term used in the SEC submission.
126:
390:
88:
32:
20:
84:
pharmaceutical company by conducting discovery, development and further commercialization of therapeutics.
242:"Horizon Technology Finance Corporation (HRZN) Stock Price, News, Quote & History - Yahoo Finance"
27:
therapeutics to treat a variety of human diseases. As of March 2014, the company was based in
351:
177:
81:
167:
92:
69:
24:
99:
40:
364:
73:
56:
127:"Form 10-K: Ambit Biosciences Corporation. Commission file number: 001-35919"
28:
181:
241:
102:. The prime asset that drove this deal was Ambit's quizartinib (AC220).
76:, Genechem, Radius Ventures, NovaQuest and Horizon Technology Finance.
55:
As of March 2014, three products were under development, of which
172:
155:
44:
36:
200:"Foresite Capital Reloads With New $ 300M Late-Stage Biotech Fund"
72:, Forward Ventures, Roche Venture Fund, MedImmune Ventures, GIMV,
31:, California, and consisted of a single facility. Ambit made an
266:"Ambit Biosciences Completes $ 30 Million Series D-2 Financing"
224:"Daiichi Sankyo to Acquire Ambit Biosciences for Up to $ 410M"
87:
Among the firms who invested heavily in Ambit prior to its
317:"Daiichi Sankyo bags leukemia drug in $ 410M Ambit buyout"
133:. U.S. Securities and Exchange Commission. March 20, 2014
39:
exchange under the symbol "AMBI". Ambit was acquired by
381:
Defunct pharmaceutical companies of the United States
292:"Local biotech turning to Japan for partnerships"
228:GEN - Genetic Engineering and Biotechnology News
8:
386:Health care companies based in California
171:
98:In November 2014, Ambit was acquired by
371:Companies formerly listed on the Nasdaq
343:
111:
43:in 2014 and is no longer traded on the
7:
193:
191:
149:
147:
121:
119:
117:
115:
35:in May 2013, and was listed on the
23:company focused on development of
14:
290:Fikes, Bradley J. (2017-01-16).
154:Huggett, Brady (December 2013).
59:was their lead drug candidate.
1:
376:Companies based in San Diego
315:Carroll, John (2014-09-28).
296:The San Diego Union-Tribune
407:
198:Fidler, Ben (2014-04-01).
89:initial public offering
33:initial public offering
270:www.businesswire.com
230:. 29 September 2014.
160:Nature Biotechnology
352:biopharmaceuticals
246:finance.yahoo.com
166:(12): 1068–1071.
95:in January 2013.
398:
355:
348:
331:
330:
328:
327:
312:
306:
305:
303:
302:
287:
281:
280:
278:
277:
262:
256:
255:
253:
252:
238:
232:
231:
220:
214:
213:
211:
210:
195:
186:
185:
175:
173:10.1038/nbt.2766
156:"Burning bright"
151:
142:
141:
139:
138:
123:
93:Foresite Capital
70:OrbiMed Advisors
25:kinase inhibitor
19:was an American
406:
405:
401:
400:
399:
397:
396:
395:
361:
360:
359:
358:
349:
345:
340:
335:
334:
325:
323:
314:
313:
309:
300:
298:
289:
288:
284:
275:
273:
264:
263:
259:
250:
248:
240:
239:
235:
222:
221:
217:
208:
206:
197:
196:
189:
153:
152:
145:
136:
134:
125:
124:
113:
108:
65:
53:
12:
11:
5:
404:
402:
394:
393:
391:Daiichi Sankyo
388:
383:
378:
373:
363:
362:
357:
356:
342:
341:
339:
336:
333:
332:
307:
282:
257:
233:
215:
187:
143:
110:
109:
107:
104:
100:Daiichi Sankyo
64:
63:Business model
61:
52:
49:
41:Daiichi Sankyo
21:pharmaceutical
13:
10:
9:
6:
4:
3:
2:
403:
392:
389:
387:
384:
382:
379:
377:
374:
372:
369:
368:
366:
353:
347:
344:
337:
322:
321:FierceBiotech
318:
311:
308:
297:
293:
286:
283:
271:
267:
261:
258:
247:
243:
237:
234:
229:
225:
219:
216:
205:
201:
194:
192:
188:
183:
179:
174:
169:
165:
161:
157:
150:
148:
144:
132:
128:
122:
120:
118:
116:
112:
105:
103:
101:
96:
94:
90:
85:
83:
77:
75:
71:
62:
60:
58:
50:
48:
46:
42:
38:
34:
30:
26:
22:
18:
346:
324:. Retrieved
320:
310:
299:. Retrieved
295:
285:
274:. Retrieved
272:. 2011-06-10
269:
260:
249:. Retrieved
245:
236:
227:
218:
207:. Retrieved
203:
163:
159:
135:. Retrieved
130:
97:
86:
78:
66:
54:
16:
15:
74:GrowthWorks
57:quizartinib
365:Categories
326:2019-12-05
301:2017-06-27
276:2019-12-05
251:2022-12-08
209:2017-06-27
137:2017-06-27
106:References
82:life cycle
47:exchange.
29:San Diego
182:24316634
51:Products
204:Xconomy
180:
45:NASDAQ
37:NASDAQ
338:Notes
131:EDGAR
17:Ambit
178:PMID
91:was
168:doi
367::
319:.
294:.
268:.
244:.
226:.
202:.
190:^
176:.
164:31
162:.
158:.
146:^
129:.
114:^
329:.
304:.
279:.
254:.
212:.
184:.
170::
140:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.